IOCB Prague is a 600+ person research institute under the Czech Academy of Sciences, operating across 45 chemistry and biochemistry groups. The tech stack—LC-MS, ICP-MS, computational chemistry tools (MPI, CMake, Nextflow)—reflects a lab-heavy, instrument-driven operation focused on synthesis and materials characterization. Active projects cluster around enantioselective catalysis, helicene design, and chelator chemistry, with stated pain points in photochemical reactivity modeling and sustainable sourcing of critical metals.
IOCB Prague conducts fundamental research in organic chemistry, biochemistry, and materials science, with particular emphasis on medicinal chemistry and natural compound chemistry. The institute publishes over 250 papers annually in high-impact journals and operates a dedicated technology transfer arm (IOCB TTO) to commercialize discoveries into patents and industry partnerships. Research groups span classical synthetic chemistry, theoretical and physical chemistry, analytical methods, and molecular biology, serving both academic audiences and pharmaceutical/materials partners seeking novel compounds and catalytic processes.
IOCB Prague specializes in chemical biology, medicinal chemistry, organic synthesis, catalysis (especially enantioselective), biochemistry, molecular biology, and analytical chemistry. Active projects include helicene-derived luminophores, transition metal catalysis, and chelator design for metal recovery.
The institute uses LC-MS and ICP-MS for analytical work, alongside computational chemistry infrastructure including MPI, CMake, Nextflow, Python, and Ansible for simulation and workflow automation.
Yes. IOCB TTO, the institute's subsidiary, supports patent filing and technology transfer, matching research results with commercial partners to bring novel compounds and processes to market.
Other companies in the same industry, closest in size